News
QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses. The new assays for the
QIAGEN führt neue CE-IVD-zertifizierte Tests für das integrierte PCR-Testsystem NeuMoDx ein
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) erweitert sein umfassendes NeuMoDx-Testmenü für Viren, die nach Organtransplantationen Infektionen auslösen können. Die neuen Tests zur
LivaNova Board Appoints Brooke Story as a New Director
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15
Thomas Jefferson University and Acadia Healthcare Establish Primary Affiliation Agreement
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) and Thomas Jefferson University today announced that Acadia’s Belmont Behavioral Health Hospital has entered into a formal affiliation agreement with
QIAGEN und Neuron23 entwickeln Next-Generation-Sequencing-Begleitdiagnostikum für neuartiges Parkinson-Medikament
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) und Neuron23 Inc., ein junges Biotechnologieunternehmen, das sich auf die Entwicklung von Präzisionsarzneimitteln für genetisch definierte
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and
Select Acadia Healthcare Hospitals to Participate in Clinical Trial for Acute Suicidal Ideation and Behavior in Major Depression Drug
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that select facilities from its network of acute care behavioral health hospitals will participate in a registration directed trial to
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Convatec Group PLC: Scrip Dividend – Calculation Price
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Xencor Appoints Nancy Valente, M.D., to Board of Directors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences in New York, including:
-
Baird 2022 Global Healthcare
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Premier, Inc.’s Subsidiary Contigo Health, LLC, to Acquire Contracts With 900,000 Providers and Licenses to Cost Containment Technology
Premier, Inc. (NASDAQ: PINC) subsidiary Contigo Health, LLC, a provider of comprehensive services that optimize employee health benefits, today announced an agreement to acquire key assets from
ICON Releases its 2021 ESG Report
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its 2021 Environmental, Social and Governance (ESG) Report.
The report outlines
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) and Cure AP-4, a non-profit foundation dedicated to raising funds and awareness about Adapter-Protein 4 Hereditary Spastic Paraplegia
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
ICON plc to Present at the 2022 Wells Fargo Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Wells Fargo
Novocure to Participate in Upcoming Investor Conferences
Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology
Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in The European Journal of Endocrinology